Emmessar Biotech

Emmessar_Biotech04 Mar 2024
Chemicals
+1.94 (+4.99%)
Lowest Today
Highest Today
Today’s Open
Prev. Close
52 Week High
52 Week Low
To Invest in Emmessar Biotech
Emmessar Biotech
Chemicals
Emmessar_Biotech04 Mar 2024
+1.94 (+4.99%)
OverviewFundamentals
1D
1M
6M
1Y
5Y
All

Emmessar Biotech - Share Price & Details

Lowest Today
40.8
Highest Today
40.8
Today’s Open
40.8
Prev. Close
38.86
52 Week High
47.69
52 Week Low
21.1
Traded Volume
Market Cap(Cr)
Avg Traded Price
1 Year return
40.46%
Upper Circuit
Lower Circuit
P/E TTM
33.5
P/B Ratio
2.81
Traded Value(Cr)
0.00
EPS TTM
1.16
Book value
Dividend
0.00%

Price Performance

0.46 %
1 Wk
22.23 %
1 M
43.95 %
3 M
40.46 %
1 Y
36.52 %
YTD

Traded Volume Movement

Technical Details

Support 3
0
Support 2
0
Support 1
0
Pivot Point :
0
Resistance 1
0
Resistance 2
0
Resistance 3
0

Peer Comparison

Scrip NamePriceDaily ChangeM.Cap (Cr)1 Year Returns %P/E (TTM)PB Ratio
40.80+1.9419.4340.4633.502.81
BASF India Ltd
₹3,313.10(-1.50/-0.05%)
3,313.10-1.5014,348.9043.0330.344.90
DIC India Ltd
₹473.00(-4.80/-1.00%)
473.00-4.80438.5726.34394.881.11
Bhagawati Oxygen Ltd
₹48.40(0.00/0.00%)
48.40+0.0011.1813.377.661.65
Oriental Aromatics Ltd
₹350.00(-5.10/-1.44%)
350.00-5.101,195.040.000.001.92
Atul Ltd
₹6,126.20(-51.10/-0.83%)
6,126.20-51.1018,187.06-13.7345.683.77

About Emmessar Biotech & Nutrition Ltd

Emmessar Biotech & Nutrition Ltd is in the Chemicals sector, having a market capitalization of Rs. 19.43 crores. It has reported a sales of Rs. 0.33 crores and a net profit of Rs. 0.13 crores for the quarter ended December 2018. The company management includes MSR Ayyangar, MSR Ayyangar,Anuradha Raghavan,Sarada Raghavan,Anantharama Sethmani Subramanian,Jayavel Balaiah Nadar,Rajalakshmi Srinivasa Raghavan,Priyanka Omprakash Sharma,Milind S Desai (Emmessar Biotech & Nutrition Ltd) among others.
Chairman
MSR Ayyangar
Registered office
Plot No T-3/2 MIDC Area,P O Box No 39 Taloja,Raigad,Maharashtra,410208
FAX :
Background
Incorporation Year1992
Face Value₹10
Market Lot1

Latest News

Large caps likely to outperform broader market: Analysts
The Indian market is poised to maintain its positive momentum, with large-cap stocks expected to outperform the broader market. This trend is indicated by the Nifty vs Nifty 500 ratio reaching its lowest point. Analysts anticipate Nifty to climb towards 22,800, provided it remains above 22,300. Some of the recommended stocks include Reliance Industries, Axis Bank, ICICI Bank, SBI, Infosys.
04 Mar 2024 | 10:05 AM
Chartist Talks | What makes Rohit Srivastava of India charts bullish?
After the Nifty 50 hit a new record high last week, the trendline indicated a new resistance near 22,360. The index needs to trade above this level for a few days to prove that the breakout from consolidation was sustainable, according to Rohit Srivastava, founder of Strike Money Analytics and India charts. The veteran with nearly three decades spent in the equity markets.
04 Mar 2024 | 09:53 AM
Stocks To Watch: ZEE, JIO Financials, Paytm, Axis Bank, Asian Paints!
GIFT Nifty indicated that Indian equity indices BSE Sensex and NSE Nifty 50 may see a positive opening on Monday. Here’s a look at the key stocks to watch in trade. Stocks in Focus: GIFT Nifty traded up by 60.50 points or 0.27% at 22,511 indicating a positive opening for domestic indices NSE Nifty 50 and BSE Sensex on Monday.
04 Mar 2024 | 09:32 AM
📢 Benchmark indices open on a flat note today; Nifty near 22,402.
📈 Amid mixed global cues, benchmark indices started on a flat note today. 📊 At 9:16 AM, the Sensex gained 96.94 points or 0.13% at 73,903.09 and the Nifty was up 25.10 points or 0.11% at 22,401.50. 📢NTPC (⬆️2.19%), and Nifty Energy (⬆️0.67%) appeared as the top performers on the Nifty50 at open. Tata Steel and JSW Steel are in focus today.
04 Mar 2024 | 09:21 AM
These pharma and healthcare microcap multibaggers turned MF favourites!
After putting up a tepid performance in 2022, pharma and healthcare funds made a strong comeback over the last 15 months with the Nifty Pharma index significantly outperforming the Nifty 50. Experts attribute this to a stable pricing environment in the US. So far this year, the pharmaceutical funds category yielded 10 percent returns, while the Nifty 50 index gained only 1 percent.
04 Mar 2024 | 09:14 AM
Click here to see your activities